| Literature DB >> 31583040 |
Małgorzata Maraj1, Beata Kuśnierz-Cabala2, Paulina Dumnicka3, Katarzyna Gawlik2, Dorota Pawlica-Gosiewska2, Agnieszka Gala-Błądzińska4,5, Anna Ząbek-Adamska6, Piotr Ceranowicz1, Marek Kuźniewski7.
Abstract
Over 50% of end-stage renal disease (ESRD) patients die of cardiovascular disease. ESRD patients treated with maintenance hemodialysis are repeatedly exposed to oxidative stress. The aim of the study was to find the relationship between lifestyle factors, nutritional status, calcium-phosphate metabolism, and selected redox parameters such as glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), uric acid (UA), and total antioxidant capacity expressed as ferric reducing antioxidant power (FRAP). The study included 97 ESRD hemodialysis patients and 42 controls with no renal disease. Patients were asked to complete a questionnaire which gathered information on their physical activity, hours of sleep, smoking, and frequency of fruit and vegetable intake; the blood samples were then drawn before the midweek dialysis session. The ESRD patients had lower levels of GR, GPx, and SOD activity, a lower level of FRAP, and a higher UA concentration than the control group. The FRAP value decreased with age (ρ = -0.32, p = 0.001); smokers had a significantly lower SOD activity in comparison to nonsmokers (p = 0.03). In the ESRD patients, FRAP and UA correlated with both albumin (ρ = 0.26, p = 0.011; ρ = 0.41, p = 0.006, respectively) and prealbumin (ρ = 0.34, p ≤ 0.001; ρ = 0.28, p = 0.006, respectively), whereas UA, GR, GPx, and SOD correlated with calcium, UA, GR, and GPx with phosphate level. Based on the findings, there are weak associations between nutritional status and selected redox parameters in hemodialyzed patients. Further studies are needed to establish if diet modifications and adequate nutritional status can positively impact the antioxidant capacity in this group of patients.Entities:
Mesh:
Year: 2019 PMID: 31583040 PMCID: PMC6748197 DOI: 10.1155/2019/6309465
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Demographic data and selected laboratory results in the ESRD patients and control group.
| Laboratory parameters | ESRD patients ( | Control group ( |
| Reference range |
|---|---|---|---|---|
| Age (years) | 62 ± 14 | 52 ± 18 | ≤0.001 | Not applicable |
| Males ( | 60 (61.9) | 17 (40.5) | 0.023 | Not applicable |
| Albumin (g/L) | 39.4 (36.4–42.8) | 44.5 (40.3–47.0) | <0.001 | 35–52 |
| Prealbumin (g/L) | 0.27 (0.22–0.32) | No data | — | 0.20–0.40 |
| CRP (mg/L) | 5.75 (2.2–13.7) | 1.45 (1.0–1.4) | ≤0.001 | <5 |
| PLT (×103/ | 203 ± 67.4 | 240 ± 66 | 0.005 | 125–340 |
| WBC (×103/ | 6.5 (5.1–7.8) | 5.8 (5.3–6.8) | 0.267 | 4–10 |
| Total cholesterol (mmol/L)∗ | 4.2 ± 1.4 | 5.2 ± 0.8 | <0.001 | 3.2–5.2 |
| LDL cholesterol (mmol/L)∗ | 2.3 ± 1.1 | 2.9 ± 0.9 | <0.001 | 0.2–3.4 |
| HDL cholesterol (mmol/L)∗ | 1.0 ± 0.3 | 1.5 ± 0.4 | 0.022 | 0.9–3.0 |
| Triglycerides (mmol/L)∗ | 1.5 (1.2–2.2) | 1.9 (1.6–2.3) | 0.210 | 0.2–2.3 |
| Bilirubin ( | 8.5 (6.8–10.3) | 10.1 (8.7–17.2) | 0.014 | 0–21 |
| Uric acid ( | 357.9 ± 107.6 | 287.94 ± 66.37 | ≤0.001 | F: 143.0–340.0 |
| M: 202.0–416.0 | ||||
| Total calcium (mmol/L) | 1.89 (1.18–2.27) | No data | — | 2.15–2.55 |
| Phosphate (mmol/L) | 2.50 (1.65–4.50) | No data | — | 0.81–1.45 |
| iPTH (pg/mL)∗ | 174.4 (75.4–410.7) | No data | — | 14.9–56.9 |
| Iron ( | 11.80 (9.12–15.00) | No data | — | 5.83–34.50 |
| TIBC ( | 42.2 ± 10.3 | No data | — | 40.8–76.6 |
| GPS | ||||
| 0 ( | 56 (57.7) | 39 (92.9) | ||
| 1 ( | 25 (25.8) | 3 (7.1) | <0.001 | 0 |
| 2 ( | 11 (11.3) | 0 | ||
| CRP/PRE | 0.019 (0.008–0.0587) | No data | — | No data |
| Glutathione peroxidase (U/L) | 75.9 ± 35.8 | 125.9 ± 18.8 | ≤0.001 | No data |
| Glutathione reductase (U/L) | 76.7 (66.7–98.3) | 100.7 (91.0–111.6) | ≤0.001 | No data |
| FRAP (mmol/L) | 0.88 ± 0.23 | 1.10 ± 0.27 | 0.027 | No data |
| Superoxide dismutase (U/mL) | 13.2 (9.8–17.5) | 19.4 (13.6–23.9) | 0.002 | No data |
LDL—low-density lipoprotein; HDL—high-density lipoprotein; iPTH—intact parathyroid hormone; PLT—platelet counts; WBC—white blood cells; TIBC—total iron binding capacity; GPS—Glasgow Prognostic Score; PRE—prealbumin; CRP—C-reactive protein; F—females; M—males; FRAP—ferric reducing antioxidant power. ∗Due to local differences in patient monitoring, lipid profiles and iPTH were only available for 44 patients treated in Rzeszow, Poland.
Clinical characteristics and lifestyle factors in the ESRD patients.
| Characteristic | ESRD patients ( |
|---|---|
| Dialysis therapy duration (months) | 63 (36–144) |
|
| |
| Smokers ( | 17 (17.5) |
|
| |
| Comorbid conditions ( | 80 (81.6) |
| Diabetes mellitus ( | 25 (25.7) |
| Hypertension ( | 57 (58.8) |
| Osteoporosis ( | 22 (22.7) |
| Periodontal disease ( | 8 (8.2) |
| Autoimmunological disease ( | 4 (4.1) |
|
| |
| Sleep | |
| 6 hours or less/day ( | 32 (33.0) |
| 7-8 h/day ( | 48 (49.5) |
| 9 hours or more/day ( | 15 (15.5) |
|
| |
| Physical activity | |
| Moderate ( | 44 (45.4) |
| Low ( | 51 (52.6) |
|
| |
| Fruit frequency | |
| ≥One portion/day ( | 57 (58.8) |
| <One portion/day ( | 36 (37.1) |
|
| |
| Vegetable frequency | |
| ≥One portion/day ( | 50 (51.5) |
| <One portion/day ( | 42 (43.3) |
|
| |
| BMI (kg/m2) | |
| Women | 24.5 ± 5.8 |
| Men | 25.7 ± 4.4 |
Abbreviations: BMI—body mass index; N—number of patients; ESRD—end-stage renal disease.
Differences between ESRD patients and controls assessed by logistic regression adjusted for sex, age, and CRP. Odds ratios (OR) for being in the study group are reported with 95% confidence intervals (CI).
| Adjusted for sex and age | Adjusted for sex, age,and CRP | |||
|---|---|---|---|---|
| OR (95% CI) |
| OR (95% CI) |
| |
| Glutathione peroxidase (per 1 U/L) | 0.94 (0.92; 0.98) | ≤0.001 | 0.97 (0.95; 0.98) | ≤0.001 |
| Glutathione reductase (U/L) | 0.99 (0.97; 0.998) | 0.021 | 1.00 (1.98; 1.02) | 0.7 |
| FRAP (mmol/L) | 0.10 (0.01; 0.64) | 0.016 | 0.44 (0.06; 3,14) | 0.4 |
| Uric acid (per 10 | 1.07 (1.02; 1.12) | 0.011 | 1.01 (0.96; 1.06) | 0.7 |
| Superoxide dismutase (U/mL) | 0.98 (0.95; 1.02) | 0.3 | 0.91 (0.85; 0.97) | 0.003 |
CRP—C-reactive protein; FRAP—ferric reducing antioxidant power.
Figure 1Correlations between selected redox and nutritional parameters in ESRD patients: ferric reducing antioxidant power (FRAP) and prealbumin (a); uric acid (UA) and prealbumin (b); glutathione reductase (GR) and prealbumin (c); FRAP and albumin (d); UA and albumin (e); GR and total cholesterol (f); GR and LDL cholesterol (g).
The results of multiple linear regression in ESRD patients showing the associations between the redox and nutritional parameters that were independent of covariates. Standardized beta coefficients (95% confidence intervals) and p values were shown for dependent variables, and the coefficients of determination (R2) were shown for the models.
| Independent variable | Dependent variable | |||||
|---|---|---|---|---|---|---|
| FRAP (mmol/L) | Uric acid ( | Glutathione reductase (U/L) | ||||
| Model 1 | Model 2 | Model 1 | Model 2 | Model 3 | ||
| Albumin (g/L) | Not included | 0.45 (0.23; 0.68); | Not included | Not included | Not included | Not included |
| Prealbumin (g/L) | 0.26 (0.04; 0.49); | Not included | 0.27 (0.03; 0.51); | 0.27 (0.03; 0.51); | Not included | Not included |
| Total cholesterol (mmol/L) | Not included | Not included | Not included | Not included | 0.47 (0.17; 0.77); | Not included |
| LDL cholesterol (mmol/L) | Not included | Not included | Not included | Not included | Not included | 0.46 (0.15; 0.76); |
| Age (years) | -0.24 (-0.45; -0.03); | -0.05 (-0.25; 0.16); | -0.09 (-0.31; 0.13); | 0.12 (-0.11; 0.34); | 0.01 (-0.29; 0.31); | 0.01 (-0.29; 0.31); |
| Dialysis vintage (months) | 0.22 (0.02; 0.42); | 0.23 (0.03; 0.42); | 0.23 (0.02; 0.44); | 0.20 (-0.01; 0.41); | 0.19 (-0.12; 0.50); | 0.25 (-0.06; 0.55); |
| Comorbidity | 0.20 (0.01; 0.40); | 0.03 (-0.17; 0.23); | -0.02 (-0.22; 0.19); | -0.10 (-0.31; 0.12); | -0.13 (-0.44; 0.18); | -0.12 (-0.43; 0.19); |
| Log (CRP, mg/L) | 0.06 (-0.15; 0.27); | 0.23 (0.03; 0.44); | 0.17 (-0.05; 0.39); | 0.18 (-0.05; 0.51); | 0.03 (-0.28; 0.33); | 0.01 (-0.31; 0.32); |
|
| 0.25; | 0.26; | 0.16; | 0.13; | 0.29; | 0.28; |
FRAP—ferric reducing antioxidant power.
Correlations between the redox parameters and calcium and phosphate concentrations in the serum of ESRD patients.
| Calcium (mmol/L) | Phosphate (mmol/L) | |
|---|---|---|
| Glutathione peroxidase (U/L) |
|
|
| Glutathione reductase (U/L) |
|
|
| FRAP (mmol/L) |
|
|
| Uric acid ( |
|
|
| Superoxide dismutase (U/mL) |
|
|
| CRP (mg/L) |
|
|
CRP—C-reactive protein; FRAP—ferric reducing antioxidant power.